These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2248082)

  • 41. Moclobemide (Ro 11-1163) versus desipramine in the treatment of endogenous depression.
    Gabelic I; Moll E
    Acta Psychiatr Scand Suppl; 1990; 360():44-5. PubMed ID: 2248068
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Burkard WP; Bonetti EP; Da Prada M; Martin JR; Polc P; Schaffner R; Scherschlicht R; Hefti F; Müller RK; Wyss PC
    J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP; Ahmed SK; Kin NM
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients.
    Gasic S; Korn A; Eichler HG; Oberhummer I; Zapotoczky HG
    Eur J Clin Pharmacol; 1983; 25(2):173-7. PubMed ID: 6628500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium.
    Botte L; Gilles C; Evrard JL; Mesters P; Wolfrum C; Berger M; Hellstern K; Ward J
    Acta Psychiatr Scand Suppl; 1990; 360():42. PubMed ID: 2248066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The comparative influence of pyrazidol, inkazan and other antidepressant monoamine oxidase inhibitors on the pressor effect of tyramine].
    Andreeva NI; Golovina SM; Faermark MF; Shvarts GIa; Mashkovskiĭ MD
    Farmakol Toksikol; 1991; 54(2):38-40. PubMed ID: 1884793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
    Dingemanse J; Korn A; Pfefen JP; Güntert TW
    Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects.
    Bieck PR; Antonin KH
    J Clin Psychopharmacol; 1988 Aug; 8(4):237-45. PubMed ID: 3209716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
    Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
    J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment with selective and reversible monoamine oxidase inhibitors in depressed patients: is there a biological effect proportional to the dose?].
    Radat F; Berlin I; Varoquaux O; Ferreri M; Puech A
    Ann Med Psychol (Paris); 1996 Jun; 154(3):204-6. PubMed ID: 8766502
    [No Abstract]   [Full Text] [Related]  

  • 51. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M; Keller HH; Kettler R
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
    Dingemanse J; Kneer J; Fotteler B; Groen H; Peeters PA; Jonkman JH
    J Clin Psychopharmacol; 1995 Feb; 15(1):41-8. PubMed ID: 7714227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Moclobemide, imipramine and placebo in the treatment of major depression.
    Versiani M; Nardi AE; Mundim FD; Alves A; Schmid-Burgk W
    Acta Psychiatr Scand Suppl; 1990; 360():57-8. PubMed ID: 2248073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders.
    Newburn GM; Fraser AR; Menkes DB; Mullen PE
    Aust N Z J Psychiatry; 1990 Dec; 24(4):475-9. PubMed ID: 2073222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Some basic aspects of reversible inhibitors of monoamine oxidase-A.
    Da Prada M; Kettler R; Burkard WP; Lorez HP; Haefely W
    Acta Psychiatr Scand Suppl; 1990; 360():7-12. PubMed ID: 2248079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders.
    Williams R; Edwards RA; Newburn GM; Mullen R; Menkes DB; Segkar C
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):155-8. PubMed ID: 8468437
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety, tolerability and efficacy of the reversible monoamine oxidase inhibitor RS-8359 in early clinical trials.
    Püchler K; Plenker A; Volz HP
    Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 5():S31-6. PubMed ID: 9466167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pre-clinical pharmacology of moclobemide. A review of published studies.
    Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
    Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RIMA: a safe concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.